Drug Type Mesenchymal stem cell therapy |
Synonyms- |
Target- |
Action- |
Mechanism Cell replacements |
Therapeutic Areas |
Active Indication |
Inactive Indication- |
Originator Organization |
Active Organization |
Inactive Organization- |
License Organization- |
Drug Highest PhasePhase 2 |
First Approval Date- |
Regulation- |
Indication | Highest Phase | Country/Location | Organization | Date |
---|---|---|---|---|
Ovarian clear cell adenocarcinoma | Phase 2 | United States | 13 Mar 2015 | |
Ovarian mixed epithelial carcinoma | Phase 2 | United States | 13 Mar 2015 | |
Ovarian Serous Adenocarcinoma | Phase 2 | United States | 13 Mar 2015 | |
Platinum-Resistant Fallopian Tube Carcinoma | Phase 2 | United States | 13 Mar 2015 | |
Platinum-Resistant Ovarian Carcinoma | Phase 2 | United States | 13 Mar 2015 | |
Primary clear cell peritoneal carcinoma | Phase 2 | United States | 13 Mar 2015 | |
Primary Peritoneal Serous Adenocarcinoma | Phase 2 | United States | 13 Mar 2015 | |
Recurrent Primary Peritoneal Carcinoma | Phase 2 | United States | 13 Mar 2015 | |
Undifferentiated Ovarian Carcinoma | Phase 2 | United States | 13 Mar 2015 | |
Brenner Tumor | Phase 2 | United States | 25 Apr 2014 |